Solutions & R&D services

Biopharma & CRO organoid studies

Build an organoid study around your candidate and program priorities across efficacy, immuno-oncology, ADC and safety.

Biopharma & CROView all services ↗

Candidate evaluation Safety & drug delivery

Candidate studies

Candidate evaluation

Compare single agents, dose responses and combinations with modality-relevant efficacy, immune and mechanism readouts.

4 services

Dose-related morphology in two breast cancer PDO models from a representative plate-based ADC study

Organoid efficacy screening

Compare single agents and combinations in tumor PDOs and other selected human organoid models to identify dose responses and differences across models.

↗

Cell-death flow readouts under control and immune-checkpoint-blockade conditions in PDO 2.0

Immuno-oncology

Evaluate immune activation and tumor-cell killing in PDO 2.0 / ALI models or immune co-cultures, with tissue imaging and functional assays tailored to your candidate.

↗

PDAC source tissue, PDO bright-field, PDO histology and CK19/CD3 immunofluorescence

PDAC PDO 2.0 · CK19 and CD3 tissue profiling03

Antibody, multispecific & T-cell engager (TCE) studies

Compare tumor-cell killing, immune activation and cytokine changes for antibody, multispecific and TCE candidates in human tumor organoids and suitable immune co-cultures.

↗

Morphology and dose response after ADC treatment in two breast cancer PDO models

ADC research

Combine target expression, spatial distribution, cytotoxicity and bystander-effect readouts in an organoid study matched to the candidate ADC.

↗

Safety & drug delivery

Examine in vitro injury-response windows, with barrier or transport assays where the study calls for them.

2 services

Human kidney organoid bright-field morphology before and 24/48 hours after doxorubicin exposure

Safety & toxicology

Compare dose- and exposure-related responses in relevant normal-tissue organoids, using morphology, function and injury markers to investigate organ risk.

↗

Bright-field, AT1, AT2, DAPI and merged views of lung organoids under normal and LPS conditions

Normal lung · LPS injury

Kidney injury-related qPCR readouts after cisplatin exposure in H9-derived kidney organoids

Human kidney organoid · cisplatin response02

Multi-organ safety in human organoids

Compare normal kidney, lung and GI organoids with adjacent non-tumor liver or other relevant models in a coordinated exposure design to rank organ risks and focus follow-up safety studies.

↗

Not sure where to start?

Tell us about your candidate, sample context and program priorities; our scientists will recommend the model, assay panel and study plan.

Discuss the study objective